Literature DB >> 16641861

Polycystic ovarian disease: the adrenal connection.

George B Marouliss1, Ioannis K Triantafillidis.   

Abstract

Polycystic ovarian disease (PCOD) is characterized by hyperandrogenemia, ovulatory dysfunction and polycystic ovaries (PCO). The increased androgen production in PCOD comes primarily from the ovaries. However, in about 40% of patients there is excessive adrenal androgen production (DHEA, DHEA-Sulfate, Androstenedione, Testosterone and Dihydrotestosterone). The contribution of the adrenal in the PCOD is suggested by the presence of adrenal androgen excess in PCO, the presence of PCO in women with enzymatic adrenal hyperplasia as well as in women with adrenal tumors. However, the cause of adrenal androgen hypersecretion is not yet fully understood but it may include endogenous hypersecretion of the zona reticularis of unclear cause, hypersecretion of cortical-androgen-stimulating hormone (CASH), stress, hyperprolactinemia, adrenal enzymatic defects etc. This short review covers the aspects of adrenal androgen hypersecretion in PCOD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16641861

Source DB:  PubMed          Journal:  Pediatr Endocrinol Rev        ISSN: 1565-4753


  3 in total

Review 1.  Testosterone physiology in resistance exercise and training: the up-stream regulatory elements.

Authors:  Jakob L Vingren; William J Kraemer; Nicholas A Ratamess; Jeffrey M Anderson; Jeff S Volek; Carl M Maresh
Journal:  Sports Med       Date:  2010-12-01       Impact factor: 11.136

2.  Endocrinological Roles for Testosterone in Resistance Exercise Responses and Adaptations.

Authors:  David R Hooper; William J Kraemer; Brian C Focht; Jeff S Volek; William H DuPont; Lydia K Caldwell; Carl M Maresh
Journal:  Sports Med       Date:  2017-09       Impact factor: 11.136

3.  Association between testosterone and serum soluble α-klotho in U.S. males: a cross-sectional study.

Authors:  Zilong Zhang; Shi Qiu; Xinyi Huang; Kun Jin; Xianghong Zhou; Tianhai Lin; Xiaoli Zou; Qiuxiang Yang; Lu Yang; Qiang Wei
Journal:  BMC Geriatr       Date:  2022-07-11       Impact factor: 4.070

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.